Who is sponsoring NCT03886441?

NCT03886441 is sponsored by Tongji University.

What drugs are being tested in NCT03886441?

Interventions in NCT03886441: Beclomethasone propionate.

What condition does NCT03886441 study?

NCT03886441 studies Locally Advanced Non Small Cell Lung Cancer.

Is NCT03886441 still recruiting?

NCT03886441 is currently status unknown. Last updated 26 March 2019.

Last reviewed 2019-03-26 · How we verify

NCT03886441

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevention of Locally Advanced NSCLC Radiotherapy Pneumonia by Inhaling Beclomethasone Propionate

Status unknown Phase 2 Last updated 26 March 2019

What this trial tests

Phase 2 trial testing Beclomethasone propionate in Locally Advanced Non Small Cell Lung Cancer in 194 participants. Status unknown.

Timeline

1 April 2019

Primary endpoint
30 September 2020

30 December 2020

Quick facts

Lead sponsor	Tongji University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	194
Start date	1 April 2019
Primary completion	30 September 2020
Estimated completion	30 December 2020
Sites	1 location across China

Drugs / interventions tested

Beclomethasone propionate — full drug profile →

Conditions studied

Locally Advanced Non Small Cell Lung Cancer — all drugs for Locally Advanced Non Small Cell Lung Cancer →

Sponsor

Tongji University

Who can join

Adults 18 to 70, any sex, with Locally Advanced Non Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Radical radiotherapy is the main treatment of locally advanced lung cancer, and radiation pneumonia is the main toxic effects of radiotherapy. Among them, the fatality rate of severe radiation pneumonia can reach 50%, which is very harmful to tumor patients. At present, the treatment mode of radiation pneumonia is very few, and the therapeutic effect is poor. The prevention of radiation pneumonitis may be the best way to reduce the number of patients with Post-radiotherapy pneumonia. Previous small clinical studies have shown that the incidence of radiation pneumonia in inhaled beclomethasone group (2 /28) was significantly lower than that in oral prednisone group (8 /29) during radiotherapy. The purpose of this study was to compare the efficacy and safety of radiotherapy between the therapeutic group (inhaled beclomethasone during radiotherapy) and the control radiotherapy group (patients received radiotherapy only), especially the incidence of radiation-induced pneumonia within half a year.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Locally Advanced Non Small Cell Lung Cancer

Currently open trials in the same condition.

NCT06066138 — A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing · Phase 1 · recruiting

Other Tongji University trials

Trials by the same sponsor.

NCT07361237 — A Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor E · Phase 1 · recruiting
NCT07208123 — Mechanistic Studies of Chronic COPD Using Single-Cell Sequencing and Single-Cell Spatial Transcriptomics · not yet recruiting
NCT07047859 — Clinical Investigation of Sympathetic Nerve Width Measurement in Thoracoscopic Sympathectomy · not yet recruiting
NCT07074704 — tACS to Improve Negative Symptoms & Cognition in Long-term Hospitalized Schizophrenia Patients. · NA · enrolling by invitation
NCT06740188 — Trazodone on NREM Sleep Stage Ⅲ in Depressed Insomniac Co-morbid Patients · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03886441 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tongji University
Last refreshed: 26 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03886441.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing